نتایج جستجو برای: rmnl encapsulated eptifibatide

تعداد نتایج: 17077  

Journal: :Journal of the American College of Cardiology 2007
John J Pippin

hese failed procedures, an additional analysis was stated a priori in etail in the statistical analysis plan prior to unblinding in which he lowest (i.e., worst) CFR from the prior ESPRIT (Enhanced uppression of the Platelet IIb/IIIa Receptor with Integrilin herapy) substudy (0.55) was imputed to those patients with a ailed procedure. When patients with a failed procedure were ncluded in the an...

Journal: :Interdisciplinary Neurosurgery 2021

Abstract Background Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and stenting angioplasty is a topic consistently debated due to concerns over safety efficacy. Tirofiban glycoprotein used throughout the world now more commonly MT. We report analysis of all AIS patients treated with Eptifibatide + MT vs. Tirofiban + MT. Methods Using pros...

Journal: :Blood 2002
Daniel W Bougie Peter R Wilker Elizabeth D Wuitschick Brian R Curtis Mohammad Malik Stewart Levine Richard N Lind Jaime Pereira Richard H Aster

Acute thrombocytopenia is a recognized complication of treatment with GPIIb/IIIa inhibitors whose cause is not yet known. We studied 9 patients who developed severe thrombocytopenia (platelets less than 25 x 10(9)/L) within several hours of treatment with the GPIIb/IIIa inhibitors tirofiban (4 patients) and eptifibatide (5 patients). In each patient, acute-phase serum contained a high titer (ra...

Journal: :Circulation 2002
Marino Labinaz Rakhi Kilaru Karen Pieper Steven P Marso Michael M Kitt Maarten L Simoons Robert M Califf Eric J Topol Paul W Armstrong Robert A Harrington

BACKGROUND Patients with prior CABG with a subsequent non-ST-segment elevation acute coronary syndrome (ACS) pose an increasingly important clinical problem. Although GP IIb/IIIa inhibitors have improved the outcome of patients with ACS, their efficacy in patients with prior CABG has not been previously evaluated. Methods and Results- We analyzed the 30- and 180-day outcomes of patients with pr...

Journal: :Blood 2003
Rosemarie A Reiter Florian Mayr Hannes Blazicek Elisabeth Galehr Petra Jilma-Stohlawetz Hans Domanovits Bernd Jilma

Whereas bleeding is the most frequent adverse event encountered in patients receiving glycoprotein (GP) IIb/IIIa inhibitors, there are currently no recommendations for how to treat such patients. The present study tested the hypothesis that infusion of desmopressin (DDAVP) reverses the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors (+l-aspirin). Study group 1 (10 healthy volunte...

Journal: :The American journal of cardiology 2006
Gian B Danzi Cinzia Capuano Marco Sesana Luigi Mauri Fabiola B Sozzi

The Ultegra Rapid Platelet Function Assay was used to measure the inhibition of platelet aggregation at baseline and 10 minutes and 8 hours after starting therapy in 114 patients undergoing high-risk percutaneous coronary intervention with the planned use of a glycoprotein IIb/IIIa inhibitor. The abciximab-treated patients received a 0.25 mg/kg bolus, followed by a 0.125 microg/kg/min infusion ...

Journal: :Current medical research and opinion 2012
S H Lang N Manning N Armstrong K Misso A Allen M Di Nisio J Kleijnen

OBJECTIVE To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antagonists (eptifibatide and abciximab). Results were analysed by drug administration with planned percutaneous coronary intervention (PCI) or as medical management without planned PCI, and separately for STEMI or NSTE ACS patients. RESEARCH DESIGN AND METHODS A systematic review was performed of ra...

2013
Michelle A. Berny‐Lang Joseph A. Jakubowski Atsuhiro Sugidachi Marc R. Barnard Alan D. Michelson Andrew L. Frelinger

BACKGROUND New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be used in combination with glycoprotein (GP) IIb-IIIa antagonists, but their combined effect on platelet function and procoagulant activity is not well studied. Therefore, the objective of this study was to evaluate the independent and complementary effects of P2Y12 and GP...

Journal: :Stroke 2013
Arthur M Pancioli Opeolu Adeoye Pamela A Schmit Jane Khoury Steven R Levine Thomas A Tomsick Heidi Sucharew Claudette E Brooks Todd J Crocco Laurie Gutmann Thomas M Hemmen Scott E Kasner Dawn Kleindorfer William A Knight Sharyl Martini James S McKinney William J Meurer Brett C Meyer Alexander Schneider Phillip A Scott Sidney Starkman Steven Warach Joseph P Broderick

BACKGROUND AND PURPOSE In a previous study, 0.3 and 0.45 mg/kg of intravenous recombinant tissue plasminogen activator (rt-PA) were safe when combined with eptifibatide 75 mcg/kg bolus and a 2-hour infusion (0.75 mcg/kg per minute). The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial sought to determine the safety of a highe...

Journal: :Journal of the American College of Cardiology 2002
Rémi Choussat Gilles Montalescot Jean Philippe Collet Eric Vicaut Annick Ankri Vanessa Gallois Gérard Drobinski Ivan Sotirov Daniel Thomas

OBJECTIVES This study was designed to examine a unique and low dose of intravenous enoxaparin in elective percutaneous coronary intervention (PCI) that would be applicable to an unselected population regardless of age, weight, renal function, or use of glycoprotein IIb/IIIa inhibitors. BACKGROUND There is limited experience of anticoagulation using intravenous (IV) low-molecular-weight hepari...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید